cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Zymeworks Inc
9 own
14 watching
Current Price
$9.7
$-0.12
(-1.22%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
598.44M
52-Week High
52-Week High
10.8
52-Week Low
52-Week Low
4.11
Average Volume
Average Volume
0.48M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization598.44M
icon52-Week High10.8
icon52-Week Low4.11
iconAverage Volume0.48M
iconDividend Yield--
iconP/E Ratio--
What does the Zymeworks Inc do?
N/A
Read More
How much money does Zymeworks Inc make?
News & Events about Zymeworks Inc.
Business Wire
14days ago
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Guggenheim Oncology Conference 2023. Zymeworks management will participate in...
PR Newswire
20days ago
Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating...
Insider Monkey
1month ago
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q3 2022 Earnings Call Transcript November 9, 2022 Jazz Pharmaceuticals plc beats earnings expectations. Reported EPS is $5.17, expectations were $4.66. Operator: Good day, and thank you for standing by. Welcome to the Q3 2022 Jazz Pharmaceuticals Earnings Call...
GeekWire
1month ago
Zymeworks will receive $350 million from Jazz Pharmaceuticals in return for the right to develop and commercialize Zymeworks lead drug candidate, zanidatamab, in the U.S., Europe and Japan. The new cash builds on a $50 million payment earlier this year and comes after Tuesdays release of positive ...
Business Wire
1month ago
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference: JP Morgan Healthcare Conference. Zymeworks management will participate in one-on-one meetings...
Frequently Asked Questions
Frequently Asked Questions
What is Zymeworks Inc share price today?
plus_minus_icon
Can Indians buy Zymeworks Inc shares?
plus_minus_icon
How can I buy Zymeworks Inc shares from India?
plus_minus_icon
Can Fractional shares of Zymeworks Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Zymeworks Inc stocks?
plus_minus_icon
What is today’s traded volume of Zymeworks Inc?
plus_minus_icon
What is today’s market capitalisation of Zymeworks Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Zymeworks Inc?
plus_minus_icon
What percentage is Zymeworks Inc down from its 52-Week High?
plus_minus_icon
What percentage is Zymeworks Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$9.7
$-0.12
(-1.22%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
PULMONX CORP
PULMONX CORP
$9.19
$0.17 (1.88 %)
Valneva SE
Valneva SE
$13.75
$-0.54 (-3.78 %)
Zomedica Corp
Zomedica Corp
$0.28
$0.00 (-0.85 %)
Fusion Pharmaceuticals Inc
Fusion Pharmaceuticals Inc
$3.37
$0.02 (0.60 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
PULMONX CORP
PULMONX CORP
$9.19
$0.17 (1.88 %)
Valneva SE
Valneva SE
$13.75
$-0.54 (-3.78 %)
Zomedica Corp
Zomedica Corp
$0.28
$0.00 (-0.85 %)
Fusion Pharmaceuticals Inc
Fusion Pharmaceuticals Inc
$3.37
$0.02 (0.60 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00